Oceanpine Capital is a venture capital firm in Hong Kong that focuses on TMT, consumption upgrade, advanced manufacturing, and healthcare sectors. Founded 2017 in Central, Hong Kong Island by David Liguang Chenn, it invests in early stage ventures and late stage ventures. Its portfolio companies include Apexigen, Ansun BioPharma, Enflame, Horizon Robotics, Rgenix, 51zhaoyou.com, Tiger Brokers, and Ansun BioPharma. As of March 2020, Oceanpine Capital has made eight investments. Their most recent investment was on March 24, 2020, when Apexigen raised $65M. Oceanpine Capital has had one exit, which was Tiger Brokers.
Timeline
Founded
Funded Companies
RgenixCancer treatment company
New York City
Ansun BioPharma
San DiegoPeople
David Liguang Chenn Chenn
Chief executive officer
Adam Sun
Managing Partner
Further reading
Documentaries, videos and podcasts
Companies
Enflame
51zhaoyou.com
Ansun BioPharma
Horizon Robotics
Rgenix
Tiger Brokers
References
Oceanpine Capital
Venture capital firm
CompanyCompany attributes
Hong KongVenture Capital Firm attributes
Categories
Related Topics
Contributors
- 1
Marie Gabrielle Laguna-Bedia
Co-founder and Managing Partner of Eternus Global. Physician of internal medicine, app developer and entrepreneur - 2
Reys Phillips
A graduate of Cleveland State University with a Bachelor of Science in Education. My main hobbies include story writing and reading. - 3
Aime Anne Nisay
QA Engineer of web and mobile applications - 4
Neelam Jhaveri
Techno Geek + Gamer + Fashionista + Sense of Humor = It's ME
